A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as "Alzheimer's in a dish," the model uses cultures of mature brain cells suspended in a gel to recapitulate ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...

Eisai (ESAIY) and Biogen (BIIB ... Leqembi received the Ministry of Food and Drug Safety, or MFDS, approval in May for treatment in adult patients with mild cognitive impairment due to Alzheimer’s ...

A new study represents a significant step forward in scientists' understanding of Alzheimer's disease. A team of investigators has examined the role of two proteins found in the brain and suggest the ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...

Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington's disease after it failed a mid-stage study, the drug developer said on ...

Alzheimer’s and Huntington’s patients do have different symptoms and disease biology, but that made no difference to the ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's ...

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...